Market Data 
Markets
Replies to post #324087 on Avid Bioservices Inc (CDMO)
KBI sold to TCR with the help of Joe McMahon and why have the current BODs remained silent ?
These guys have conflicts of interest it seems.....and will they follow fiduciary Duties at Peregrine, now Avid...CDMO?
Peregrine collaborator Ambit... bought out by Hitachi... I mean Daiichi Sankyo but there are some ties... : )
...
....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132033083
JSR Corporation and KBI Biopharma, Inc. Agree to Acquisition; INCJ and CMIC of Japan also participate
Written by Admin | Sep 3, 2017 8:37:00 AM
Sunnyvale, CA and Tokyo, Japan – February 26, 2015 – JSR Corporation (JSR), along with Tokyo-based CMIC Holdings Co. Ltd. (CMIC) and Innovation Network Corporation of Japan (INCJ), announced today that they have agreed to acquire KBI Biopharma, Inc., a biopharmaceutical contract development and manufacturing organization with facilities in Durham and Research Triangle Park, North Carolina and Boulder, Colorado. Following completion of the acquisition, JSR will own the majority interest in KBI within the acquiring group.
With this acquisition, JSR continues to demonstrate its commitment to the life sciences industry, by expanding its bioprocess capabilities and gaining a strong, successful partner.
KBI is a well-established leader in contract development and manufacturing of biopharmaceutical products, with an extensive track record of successful programs for its clients. The acquisition of KBI will allow JSR to facilitate the acceleration of the company’s growth plans, with increased capacity as well as global expansion, including additional customers in Japan and Asia.
“This event is best described as the beginning of a partnership that will enable each company to continue to provide innovation for the bioprocessing development and manufacturing space,” said JSR Corporation President, Mitsunobu Koshiba. “We have been extremely impressed with KBI at the technical, management and customer service levels. We will look to KBI to enhance our bioprocess product development and increase our understanding of the market in general. We expect that KBI’s extensive experience, expertise and technology will help drive our innovation cycle.”
“Through this exciting new partnership, we will leverage the combination of KBI’s core competencies, along with the material science leadership, global presence and financial strength of our new partners,” said KBI President and CEO Joe McMahon. “In addition, with our well-aligned values and common focus on scientific innovation and customer service, we will continue our mission to improve the quality of human life by accelerating our clients’ development of innovative medicines for patients on a global basis.”
In addition to the acquisition of KBI, JSR and CMIC have entered into a joint project to develop design and manufacturing processes and process materials for the next generation of antibody pharmaceuticals. Both companies expect the new relationship with KBI to contribute greatly to the project’s success. INCJ will support this, and other development efforts, through its industry-academia- government network in Japan. The global biopharmaceutical market is forecast to expand to US$2.5 trillion in 2024, and the manufacturing process development and contract manufacturing markets are projected to grow to US$8.3 billion.
—
About JSR Corporation:
The JSR Group uses its unique polymer technology to provide synthetic rubbers, emulsions and synthetic resins, semiconductor materials, and display materials. The JSR Group is expanding its business globally with its focus on life sciences and lithium ion capacitors as strategic businesses for sustainable growth.
For details, please visit http://www.jsr.co.jp/ .
About Innovation Network Corporation of Japan (INCJ):
INCJ was established in July 2009 as a public-private partnership that provides financial, technological and management support for next-generation businesses. INCJ specifically supports those projects that combine technologies and varied expertise across industries and materialize open innovation. INCJ has the capacity to invest up to ¥2 trillion (approx. US$20 billion).
About CMIC HOLDINGS Co., Ltd.:
CMIC Group first started the CRO (Contract Research Organization) business in 1992, and currently offers a comprehensive support services for the pharmaceuticals products from Research and Development to Sales and Marketing. In addition, CMIC Group is also involved in the health care business, as well as the development and sales of diagnostic drugs and orphan drugs (an original product of CMIC).
About KBI Biopharma, Inc.:
KBI is a leading contract development and manufacturing organization focusing on biopharmaceuticals. To date, KBI has helped to advance drug development programs for over 200 clients around the world. KBI offers an extensive suite of expert development and manufacturing services through an agile, science-based and customer-focused approach.
Media Contacts:
US:
JSR Life Sciences, Missy Bindseil
mbindseil@jsrmicro.com
408-543-8945
KBI Biopharma, Inc., Andrew Cohen
acohen@kbibiopharma.com
919-479-9898
Japan:
JSR Corporation, Yoshiko Takeda
Yoshiko_takeda@jsr.co.jp
+81-3-6218-3517
https://www.google.com/amp/s/www.kbibiopharma.com/our-resources/jsr-corporation-kbi-biopharma-inc-agree-acquisition-incj-cmic-japan-participate%3fhs_amp=true
The Innovation Network Corporation of Japan(INCJ) (?????????? Kabushiki-gaisha Sangyo Kakushin Kiko), headquartered in Tokyo,[4][5] is a public-private partnership between the Japanese government and 19 major corporations.
....
....
....
Investors
The INCJ is capitalized at 112 billion yen. The Japanese government also provides guarantees up to a total of 1,800 billion yen for INCJ investments. This funding is used partly as a combination of venture capital and “buyout fund” to provide risk arbitrage to support a growth strategy of small and mid-size companies and to facilitate consolidation among established companies for the purpose of helping them become global leaders, as well as directly invest in new ventures.
The breakup of investors and their investments made are the following,
Japanese Government
The Japanese government provides 102 billion yen[5] out of the total capital of 112 billion yen. The government also provides guarantees up to a total of 1,800 billion yen for INCJ investments, giving it an investment capability of approximately 1,900 billion yen (US$24 billion).
Corporate investors
The following 19 major Japanese companies have made a total investment of 10 billion JPY.[5] Each investor has contributed 500 million yen, with the exception of DBJ, which has contributed 1 billion yen.
Asahi Kasei Corporation
Osaka Gas Co., Ltd.
Sharp Corporation
The Shoko Chukin Bank, Ltd.
Sumitomo Chemical Co., Ltd.
Sumitomo Corporation
Sumitomo Electric Industries, Ltd.
Takeda Pharmaceutical Company Limited
Tokyo Electric Power Company, Inc.
Toshiba Corporation
JGC Corporation
Development Bank of Japan Inc.
Panasonic Corporation
East Japan Railway Company
Hitachi, Ltd.
Mizuho Corporate Bank, Ltd.
The Bank of Tokyo-Mitsubishi UFJ, Ltd.
General Electric Company,Japan
JX Nippon Oil & Energy Corporation
https://en.m.wikipedia.org/wiki/INCJ
History of CMIC
.....
.....
April 1992
?Acquisition of an inactive company, and Kazuo Nakamura was appointed CEO of the new company.
This first contract research organization (CRO) in Japan was founded without existing legislation and operated out of a one-room flat. The history of CMIC directly reflects the history of CROs in Japan.
September 1994
?Founding of the Japan CRO Association with three other companies working in the field at that time.
Kazuo Nakamura served as secretariat for 5 years from establishment, and then as a chairman for 13 years (1999-2012), contributing greatly to the development of the association and the industry as a whole. The Japanese CRO market expanded to an estimated worth of 133,000 million yen during this period.
June 1996
Started clinical research coordination (CRC) services for the first time in Japan (later became the Site Support Institute)
CMIC became the first company to provide CRC/SMO (Site Management Organization) services that are essential for conducting clinical trials in Japan today. The business supports medical institutions in every aspect of conducting clinical studies.
1996
Established the first South Korean CRO as a joint venture
Taking the first step into the larger Asian market (As of 2017, there are 12 sites across Asia, including Singapore and China, as well as sites in the USA).
April 1997
?Enforcement of the new Good Clinical Practice (GCP) guidelines and legislation of CROs
?This was followed by rapid development of CROs and expansion within Japan.
August 2000
??Started a contract sales organization (CSO) (later became known as CMIC Ashfield)
?The business faced some challenges due to late market entry, but after merging with Ashfield, it came to hold the third largest market share in Japan, providing multi-channel solutions to clients’ diverse needs.
September 2001?
?Ventured into the Chinese market with CRO services
....
.....
August 2005
?Launched a contract development manufacturing organization (CDMO) (later known as CMIC CMO)
?Pharmaceutical manufacturing plants were purchased first in South Korea, and then in Japan. (Currently, we have 3 plants in Japan, 1 in the USA, and 1 in South Korea.) The company also entered the challenging field of establishing manufacturing methods for next-generation medicines.
December 2007
??Started CDMO business in the USA (CMIC CMO USA Corporation)
?.....
...
January 2012
??Became a holding company, CMIC Holdings Co., Ltd, upon divestiture
May 2012
??Established OrphanPacific, Inc., a joint venture for the manufacture and sales of pharmaceuticals, mostly orphan drugs.
?This new company utilizes domestic and overseas networks to provide a stable supply of established drugs, introduce drugs for treatment of rare diseases, and assist foreign companies without a Japanese base to enter the Japanese market.
....
....
July 2014
??Commenced development of production process of next-generation antibodies
?A joint venture was established with JSR Corporation to promote projects to discover and manufacture next-generation antibodies, aimed at providing global support services for development and manufacturing, and supplying processing materials based on the knowledge gained through the project.
May 2015?
??Established a consulting team focusing on regenerative medicines
?A consulting team specialized in regenerative medicines was also established in response to increasing demands, ahead of others in the industry.
February 2016
??Established a joint venture focusing on new pharmaceutical development in the field of oncology
?Highly specialized and experienced staff with a wealth of knowledge in oncology were intensively recruited to reinforce the business relating to new pharmaceutical development in the field of oncology.
June 2017
??Established a joint venture focused on analytical research in China
?This joint venture with Shanghai Fosun Pharmaceutical Development Co., Ltd. was established to provide analytical laboratory services for generic pharmaceuticals.
https://www.cmicgroup.com/e/
Company Overview
CMIC HOLDINGS Co., Ltd., together with its affiliates, provides support services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization Business, Contract Manufacturing Organization Business, Contract Sales Organization Business, Healthcare Business, and Intellectual Property Development Business.
https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=10850614
Peregrine / CDMO KOL Scott Antonia co patent owner Dr James Mule which were both enticed to sell out their patent ....
Florida House speaker calls for investigation into China-Moffitt ties
Speaker José Oliva taps state Rep. Chris Sprowls to find out whether China benefits from millions spent on medical research at Florida institutions.
Florida House Speaker José Oliva said Thursday that state Rep. Chris Sprowls will investigate ties between China and Tampa’s H. Lee Moffitt Cancer Center & Research Institute following Wednesday’s announcement that the center’s CEO and others have been ousted.
“The news (stories) coming out of Moffitt Cancer Center are of great concern and compel further investigation," Oliva said in a statement. “While Moffitt’s leadership acted swiftly and decisively, a deeper look into this and all of our institutions is in order.”
In an interview Thursday, Sprowls said actions by Moffitt’s CEO, Dr. Alan List, and other center employees had aided infiltration efforts by China and were indefensible. The Palm Harbor Republican, a former prosecutor, said lawmakers should take steps to make sure similar activity isn’t occurring at other academic institutions across the state.
“These research institutions benefit from vast sums of state and federal resources that are funded by American taxpayers,” said Sprowls, who is slated to succeed Oliva as House speaker. “For these researchers to receive monetary gain from the Chinese government and to pilfer our research, that is just alarming news. And I don’t believe it is isolated to Moffitt.”
State Rep. Chris Sprowls greets Florida House Speaker Jose Oliva last year after Oliva was sworn in at the Florida Capitol. On Thursday, Oliva appointed Sprowls to investigate Chinese efforts to benefit from millions spent on medical research at Florida institutions.
[SCOTT KEELER | TIMES]
Moffitt received more than $36 million this year in grants from the National Institutes of Health, one of the federal agencies investigating the extent to which China is benefiting from U.S.-based medical research.
RELATED: Moffitt Cancer Center shakeup: CEO and others resign over China ties
Moffitt’s board of directors announced Wednesday that List, along with Thomas Sellers, a vice president and director at Moffitt, and four of the cancer center’s researchers resigned under pressure because of a controversy that linked them to possible exploitation of American-funded research by China. List will continue to treat his current patients at Moffitt. He did not respond to multiple phone calls and emails requesting an interview.
Moffitt officials did not divulge whether List and others accepted money from China, but said an internal investigation revealed conflicts of interest and a lack of disclosure of international collaborators. Officials said there is no indication that Moffitt research was compromised or that patient care has been affected.
“We found evidence that people were compensated through the Thousand Talents program and failed to disclose that,” Moffitt officials disclosed Thursday.
The reference was to a program China uses as a tool to recruit talent from Western countries. Sprowls said it’s been “widely reported” that Americans involved in Thousand Talents have received monetary gains.
“I plan to take an active role in looking into the firewalls in place to protect our intellectual property and proprietary information,” Sprowls said. “The Legislature funds these institutions and we need to account for the money we’ve already spent. Taxpayers deserve to know that their money is not subsidizing the Chinese government.”
It was unclear whether Moffitt’s 12-year research and education partnership with the Tianjin Medical University Cancer Institute and Hospital, a 2,400-bed hospital outside of Beijing, is also a source of concern. Moffitt officials are reviewing the arrangement and have alerted the federal government of their preliminary findings.
Thousand Talents was one of hundreds of programs created by the Chinese government to lure back esteemed scientists to improve the quality of the country’s research and innovation, said Ross McKinney, chief scientific officer for the Association of American Medical Colleges.
“The problem wasn’t the recruitment. That happens all the time and there’s nothing wrong with it,” he said. “The problem came when scientists didn’t want to come to China, so instead they’d offer them a part-time job and instructed them not to tell anyone about it.”
Researchers would be paid for their work, sometimes in Chinese currency. Others would steal ideas from peer-reviewed proposals. In some cases, Chinese researchers would copy data and install malware on university campuses, McKinney said.
“These researchers were told to lie,” he said. “And all of a sudden, someone in China is doing the very project you proposed to do. It is a very serious structural effort on the part of the Chinese government.”
Oliva alluded to that activity in his statement Thursday.
“Floridians, and all Americans, should be greatly concerned at both the potential theft of intellectual property and the corruption it implies,” the statement said. "Compromising our public health and research institutions puts all of us at risk. The Florida House will do everything in our power to hold people, and institutions, accountable.”
In an email, NIH officials said Moffitt’s review showed “that several individuals involved in NIH grants, some of whom are members of the Moffitt Cancer Center leadership team, failed to disclose substantial contributions of resources from other organizations, foreign affiliations, and financial conflicts of interest.”
The statement also said NIH will work with Moffitt “to determine the extent of the violations and remediation actions.” The response, it said, could include the removal of more researchers and the return of grant money to the government. The agency also commended Moffitt for “identifying and disclosing these violations to NIH.”
The agency, one of the largest funding sources for medical research in the world, has launched 170 formal inquiries into American academic institutions this year where ties to China were unclear. Researchers were fired at Emory University and the University of Texas MD Anderson Cancer Center. In some cases, the FBI is involved.
“China has pioneered a societal approach to stealing innovation in any way it can from a wide array of businesses, universities and organizations," FBI Director Christopher Wray said in April. "They’re doing it through Chinese intelligence services, through state-owned enterprises, through ostensibly private companies, through graduate students and researchers, through a variety of actors all working on behalf of China.”
Wray added: “At the FBI, we have economic espionage investigations that almost invariably lead back to China in nearly all of our 56 field offices, and they span just about every industry or sector.”
But rooting out who is leaking information has been a challenge, McKinney said. The scale and scope of the problem was even difficult to define in a study released in December by JASON, an independent group of scientists which advise the U.S. government.
“We don’t know how deep it goes. We’re not good at this sort of inspection,” he said.
For decades, American medical and research institutions have forged relationships with foreign collaborators to share information and research strategy, said Jay Wolfson, a professor at the University of South Florida’s College of Public Health and an expert on health care policy.
“For years, some of our best and brightest students have come to study in America from China, South Korea, India and South American countries," he said. "Some stay and join faculty. Others return home and want to maintain those relationships. Collaboration like this improves quality of life and science.”
McKinney reiterated the point, saying the U.S. has a rich history of science being done by immigrants and in collaboration with other countries. “It’s a shame that it could be damaged by the effects this program has had on trust,” he said.
Some scientists fear the U.S. government could go too far and create regulations that would stifle future research collaborations, said William Colglazier, a senior scholar with the Center for Science Diplomacy at the American Association for the Advancement of Science.
“There are two sides of this coin," he said. “It’s in everyone’s interest that we can all benefit from any breakthroughs that happen in science, no matter where they are. The other side is that clearly China has not followed the norms and standards of ethical requirements, and they need to understand that this cannot continue.”
Any investigation by state lawmakers would look into other academic institutions in Florida beyond Moffitt, including the Mayo Clinic in Jacksonville, the University of South Florida and the University of Florida, which also receive NIH grants.
UF Health in Gainesville strengthened its processes and protocols recently due to the NIH inquiries, said spokesman Steve Orlando. That included launching a dedicated website to explain new requirements of researchers.
Earlier in the year, Moffitt officials had pitched a multi-million dollar expansion to its Tampa campus to meet greater patient needs. Sprowls said state funding for the cancer center’s expansion project isn’t off the table, but Moffitt leadership has some questions to answer first.
“It’s a separate issue," Sprowls said. “But they have to account for these unanswered questions.”
AI
